Ono Pharmaceutical Co. Lt... (OPHLY)
Ono Pharmaceutical Statistics
Share Statistics
Ono Pharmaceutical has 1.41B shares outstanding. The number of shares has increased by 3.01% in one year.
| Shares Outstanding | 1.41B |
| Shares Change (YoY) | 3.01% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 453.33M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 9.27 and the forward PE ratio is null. Ono Pharmaceutical's PEG ratio is 0.04.
| PE Ratio | 9.27 |
| Forward PE | n/a |
| PS Ratio | 2.36 |
| Forward PS | n/a |
| PB Ratio | 1.5 |
| P/FCF Ratio | 13.2 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Ono Pharmaceutical has an Enterprise Value (EV) of 238.03B.
| EV / Sales | 0.47 |
| EV / EBITDA | 1.33 |
| EV / EBIT | 2.15 |
| EV / FCF | 2.65 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.99 |
| Quick Ratio | 3.52 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.1 |
| Interest Coverage | 712.24 |
Financial Efficiency
Return on Equity is 16.14% and Return on Invested Capital is 15.7%.
| Return on Equity | 16.14% |
| Return on Assets | 14.01% |
| Return on Invested Capital | 15.7% |
| Revenue Per Employee | $130.46M |
| Profits Per Employee | $33.21M |
| Employee Count | 3,853 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.61 |
Taxes
| Income Tax | 35.69B |
| Effective Tax Rate | 21.8% |
Stock Price Statistics
The stock price has increased by -18.2% in the last 52 weeks. The beta is 0.44, so Ono Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.44 |
| 52-Week Price Change | -18.2% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 58.88 |
| Average Volume (20 Days) | 426.86K |
Income Statement
In the last 12 months, Ono Pharmaceutical had revenue of 502.67B and earned 127.98B in profits. Earnings per share was 266.57.
| Revenue | 502.67B |
| Gross Profit | 375.55B |
| Operating Income | 163.1B |
| Net Income | 127.98B |
| EBITDA | 178.44B |
| EBIT | 163.96B |
| Earnings Per Share (EPS) | 266.57 |
Balance Sheet
The company has 166.14B in cash and 8.86B in debt, giving a net cash position of 157.28B.
| Cash & Cash Equivalents | 166.14B |
| Total Debt | 8.86B |
| Net Cash | 157.28B |
| Retained Earnings | 768.18B |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was 110.66B and capital expenditures -20.83B, giving a free cash flow of 89.83B.
| Operating Cash Flow | 110.66B |
| Capital Expenditures | -20.83B |
| Free Cash Flow | 89.83B |
| FCF Per Share | 187.12 |
Margins
Gross margin is 74.71%, with operating and profit margins of 32.45% and 25.46%.
| Gross Margin | 74.71% |
| Operating Margin | 32.45% |
| Pretax Margin | 32.57% |
| Profit Margin | 25.46% |
| EBITDA Margin | 35.5% |
| EBIT Margin | 32.45% |
| FCF Margin | 17.87% |
Dividends & Yields
OPHLY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 10.79% |
| FCF Yield | 22.72% |
Analyst Forecast
Currently there are no analyst rating for OPHLY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 4, 2016. It was a forward split with a ratio of 3:1.
| Last Split Date | Apr 4, 2016 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |